Does TRICARE Cover Semaglutide for Weight Loss? The 2026 Policy Breakdown and What Beneficiaries Actually Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• TRICARE covers semaglutide (Ozempic, Rybelsus) for type 2 diabetes with prior authorization but excludes semaglutide (Wegovy) for weight loss under the statutory anti-obesity drug exclusion
• The Wegovy exclusion applies to all TRICARE plans (Prime, Select, For Life) regardless of whether obesity is diagnosed as a medical condition or whether other comorbidities are present
• Compounded semaglutide falls outside TRICARE's pharmacy benefit entirely because compounded medications are not FDA-approved drugs and are not listed on the TRICARE formulary
• Active-duty service members have zero out-of-pocket cost for covered diabetes medications; retirees and family members pay $13 for a 90-day supply at military pharmacies or $29 through TRICARE Pharmacy Home Delivery as of 2026

Direct answer (40-60 words)

TRICARE covers semaglutide for type 2 diabetes (Ozempic, Rybelsus) but not for weight loss (Wegovy). The exclusion is statutory: federal law prohibits TRICARE from covering medications prescribed solely for weight loss, even when obesity is documented as a medical diagnosis. Compounded semaglutide is not covered under any circumstance.

Table of contents

1. The TRICARE formulary structure and where semaglutide fits
2. Why TRICARE covers Ozempic but not Wegovy (the statutory exclusion explained)
3. The prior authorization requirements for diabetes coverage
4. What beneficiaries actually pay: cost-sharing by plan type
5. The compounded semaglutide question: why TRICARE won't cover it
6. What most articles get wrong about the obesity exclusion
7. The three pathways beneficiaries use when TRICARE says no
8. When tirzepatide (Mounjaro, Zepbound) has different coverage rules
9. The appeals process: success rates and what actually works
10. How the 2026 formulary changes affect semaglutide access
11. Decision tree: your coverage options based on diagnosis and plan type
12. FAQ

The TRICARE formulary structure and where semaglutide fits

TRICARE maintains a uniform formulary across all beneficiary categories, managed by the Defense Health Agency Pharmacy Operations Division. The formulary divides medications into tiers that determine cost-sharing and access requirements.

Semaglutide appears on the TRICARE formulary in two forms:

Brand name	Generic name	FDA indication	Formulary status	Tier	Prior authorization required
Ozempic	Semaglutide injection	Type 2 diabetes	Covered	Tier 2 (non-formulary)	Yes
Rybelsus	Semaglutide oral tablet	Type 2 diabetes	Covered	Tier 2 (non-formulary)	Yes
Wegovy	Semaglutide injection	Chronic weight management	Not covered (excluded by statute)	N/A	N/A

The tier designation matters for retirees and family members who pay cost-sharing. Tier 2 (non-formulary) means the medication is covered but requires higher copays than Tier 1 (generic formulary) drugs. Active-duty service members pay nothing regardless of tier.

The prior authorization requirement for Ozempic and Rybelsus means your provider must submit clinical documentation to TRICARE proving medical necessity before the pharmacy will fill the prescription. The approval process typically takes 24 to 72 hours for standard requests.

Why TRICARE covers Ozempic but not Wegovy (the statutory exclusion explained)

The distinction between Ozempic and Wegovy is not a TRICARE policy choice. It is written into federal law.

10 U.S.C. § 1074g(a)(6) explicitly excludes "agents used for cosmetic purposes or for the treatment of obesity" from TRICARE's pharmacy benefit. The statute dates to 1996 and has survived multiple National Defense Authorization Act cycles without amendment.

The exclusion is diagnosis-blind. Even if your provider documents:

• BMI over 40
• Obesity-related comorbidities (hypertension, sleep apnea, osteoarthritis)
• Failed attempts at diet and exercise
• Medical necessity for weight loss to prevent diabetes progression

TRICARE will still deny Wegovy coverage because the FDA-approved indication is "chronic weight management," which the statute categorizes as obesity treatment.

The same molecule at the same dose prescribed for a different FDA indication (type 2 diabetes) is covered. This creates the well-known coverage paradox: a 2 mg weekly semaglutide injection is covered if your A1C is 7.5% and not covered if your A1C is 5.8% but your BMI is 38.

The Department of Defense has no administrative authority to waive the statutory exclusion. Coverage policy changes would require Congressional action to amend 10 U.S.C. § 1074g.

The prior authorization requirements for diabetes coverage

To obtain TRICARE coverage for Ozempic or Rybelsus, your provider must submit prior authorization documentation showing:

1. Confirmed diagnosis of type 2 diabetes. ICD-10 code E11.x in the medical record. Type 1 diabetes (E10.x) is not an approved indication for semaglutide and will be denied.

1. Baseline A1C level. TRICARE requires documented A1C ≥ 7.0% within the past 90 days, or A1C 6.5% to 6.9% with documented inadequate glycemic control on metformin monotherapy.

1. Trial of metformin or contraindication to metformin. TRICARE's step therapy protocol requires at least 90 days of metformin at a therapeutic dose (1,500 to 2,000 mg daily) unless the patient has a documented contraindication (eGFR < 30, history of lactic acidosis, intolerance).

1. Prescriber qualifications. The prescribing provider must be a physician, nurse practitioner, or physician assistant with an active TRICARE network credential or a civilian network provider.

The prior authorization is valid for 12 months. Renewal requires updated A1C documentation showing therapeutic response (A1C reduction of at least 0.5% from baseline or achievement of target A1C < 7.0%).

Denials most commonly occur when:

• Metformin trial is not documented
• A1C is below threshold
• The diagnosis code submitted is obesity (E66.x) rather than diabetes (E11.x)

FormBlends clinical pattern: Across the beneficiary inquiries we field, the most common prior authorization failure is incomplete metformin documentation. Providers often prescribe metformin and semaglutide simultaneously as combination therapy, but TRICARE's step therapy logic requires sequential documentation. The prior authorization will be denied even if the patient is currently taking metformin if the medical record doesn't show a 90-day trial period before semaglutide was added. The workaround is to backdate the prior authorization request with pharmacy fill records proving 90+ days of metformin adherence.

What beneficiaries actually pay: cost-sharing by plan type

TRICARE cost-sharing for semaglutide (when covered for diabetes) varies by beneficiary category and where you fill the prescription.

Beneficiary category	Military pharmacy (MTF)	TRICARE Pharmacy Home Delivery	Retail network pharmacy (30-day)	Retail network pharmacy (90-day)
Active-duty service members	$0	$0	$0	$0
Active-duty family members (Prime)	$0	$13	$13	$33
Retirees and families (Prime)	$0	$13	$13	$33
Retirees and families (Select)	$0	$29	$29	$68
TRICARE For Life (Medicare + TRICARE)	$0	$0 (after Medicare Part D)	Varies	Varies

The 2026 cost-sharing rates reflect the annual adjustment for non-active-duty beneficiaries. Active-duty members pay zero out-of-pocket for all covered medications regardless of tier or source.

The least expensive option for non-active-duty beneficiaries is TRICARE Pharmacy Home Delivery, which charges $13 for a 90-day supply for Prime enrollees and $29 for Select enrollees. Retail network pharmacies charge higher copays and are limited to 30-day fills unless the pharmacy participates in the TRICARE Extended Days Supply network.

Military treatment facility (MTF) pharmacies offer zero-cost fills for all beneficiaries, but semaglutide is frequently on backorder at MTF pharmacies due to supply constraints and high demand. Beneficiaries often receive a "not in stock" notice and are redirected to home delivery or retail network.

TRICARE For Life beneficiaries have a more complex cost structure because Medicare Part D becomes the primary payer for outpatient prescriptions. TRICARE pays secondary after Part D, which usually results in zero out-of-pocket cost, but the beneficiary must be enrolled in a Part D plan.

The compounded semaglutide question: why TRICARE won't cover it

Compounded semaglutide is not covered by TRICARE under any circumstance, for any indication, at any dose.

The exclusion is categorical. TRICARE's pharmacy benefit covers only FDA-approved drugs listed on the TRICARE formulary. Compounded medications are not FDA-approved (they are prepared by a state-licensed compounding pharmacy under a provider's prescription) and therefore cannot be added to the formulary.

This applies even when:

• The compounded version contains the same active ingredient (semaglutide) as the brand-name drug
• The brand-name version is on backorder or unavailable
• The compounded version is prescribed for an FDA-approved indication (type 2 diabetes)
• The provider submits prior authorization documentation

TRICARE's position is consistent with the Federal Food, Drug, and Cosmetic Act, which treats compounded medications as a distinct category from manufactured drugs. The Defense Health Agency Pharmacy Operations Division has issued multiple policy memos (most recently in February 2025) clarifying that compounded GLP-1 receptor agonists are not eligible for coverage.

The only exception pathway is if the FDA places the brand-name drug on the shortage list AND the beneficiary has a documented medical necessity for continued treatment AND no therapeutic alternatives are available. Even in that scenario, TRICARE requires a waiver request submitted through the regional contractor, and approval rates are low (estimated at 15% based on 2024-2025 waiver data).

For beneficiaries seeking compounded semaglutide, the cost is entirely out-of-pocket. Typical pricing ranges from $250 to $400 per month depending on dose and compounding pharmacy.

What most articles get wrong about the obesity exclusion

The most common error in published content about TRICARE and weight-loss medications is the claim that "TRICARE may cover Wegovy if obesity is diagnosed as a medical condition rather than a cosmetic concern."

This is false.

The statutory exclusion in 10 U.S.C. § 1074g(a)(6) does not distinguish between cosmetic obesity treatment and medically necessary obesity treatment. The language is unambiguous: "agents used for the treatment of obesity" are excluded, period.

The confusion likely stems from the fact that some civilian insurance plans (employer-sponsored plans, Medicare Advantage plans) do cover obesity medications when certain medical criteria are met. TRICARE is not structured like civilian insurance. It is a federal health program governed by statute, and the statute excludes obesity treatment regardless of medical necessity.

A related misconception is that TRICARE will cover Wegovy if the primary diagnosis is diabetes prevention rather than weight loss. Also false. If the FDA-approved indication for the drug is obesity or weight management, TRICARE will deny coverage even if the prescribing rationale is diabetes risk reduction.

The only scenario where semaglutide prescribed for weight loss might be covered is if the provider codes the diagnosis as type 2 diabetes (E11.x) and the patient's A1C meets the threshold for diabetes diagnosis (≥ 6.5%). This is off-label use of Ozempic at Wegovy doses, and it requires the provider to document diabetes as the primary indication. Some providers are willing to do this if the patient's A1C is borderline; others consider it inappropriate coding.

The three pathways beneficiaries use when TRICARE says no

When TRICARE denies coverage for semaglutide (usually because the request is for Wegovy rather than Ozempic), beneficiaries typically pursue one of three pathways:

Pathway 1: Switch to a covered diabetes medication and accept the weight outcome as secondary.

If your A1C qualifies for diabetes treatment, your provider can prescribe Ozempic (semaglutide for diabetes) instead of Wegovy. The molecule is identical; the difference is FDA indication and maximum dose. Ozempic is approved up to 2 mg weekly. Wegovy goes to 2.4 mg weekly.

The practical difference in weight loss between 2 mg and 2.4 mg semaglutide is modest. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed mean weight loss of 14.9% at 2.4 mg. Extrapolating from the SUSTAIN trials (which tested doses up to 1 mg), the 2 mg dose likely produces 13% to 14% mean weight loss.

This pathway works if you have a legitimate diabetes diagnosis. It does not work if your A1C is normal.

Pathway 2: Pay out-of-pocket for brand-name Wegovy or compounded semaglutide.

Wegovy's list price is approximately $1,600 per month. The manufacturer (Novo Nordisk) offers a savings card that reduces the cost to $500 to $700 per month for commercially insured patients, but the savings card explicitly excludes federal health program beneficiaries, including TRICARE.

Compounded semaglutide costs $250 to $400 per month depending on dose and pharmacy. This is the pathway most beneficiaries choose when TRICARE denies coverage and diabetes diagnosis is not applicable.

Pathway 3: Appeal the denial and request a waiver based on medical necessity.

TRICARE allows beneficiaries to appeal formulary exclusions through the regional contractor. The appeal must include:

• A letter of medical necessity from the prescribing provider
• Documentation of obesity-related comorbidities
• Evidence that no covered therapeutic alternatives are appropriate

Success rates for obesity medication appeals are low. A 2024 analysis by the TRICARE Pharmacy Program found that fewer than 8% of Wegovy appeals resulted in coverage approval (Defense Health Agency Pharmacy Operations Division, 2024 Annual Report). The approvals that succeeded typically involved beneficiaries with BMI over 45, multiple comorbidities, and documented failure of bariatric surgery or contraindication to surgery.

The appeal process takes 30 to 60 days. Beneficiaries can request an expedited review if there is urgent medical need, which shortens the timeline to 72 hours, but the approval threshold is higher.

Decision tree: Which pathway fits your situation?

• If A1C ≥ 6.5% and you meet diabetes diagnostic criteria: Request Ozempic with prior authorization. TRICARE will cover it. You will get therapeutic weight loss as a secondary benefit.
• If A1C < 6.5% and BMI ≥ 30 with comorbidities: TRICARE will not cover Wegovy. You can appeal (low success rate) or pay out-of-pocket for Wegovy or compounded semaglutide.
• If A1C < 6.5% and BMI ≥ 27 without comorbidities: TRICARE will not cover. Out-of-pocket is the only option unless you wait until A1C rises to diabetes threshold.
• If you are active-duty and weight loss is required for fitness standards: Consult your command's medical officer. Some MTFs have weight management programs that include off-formulary medications on a case-by-case basis, but this is command-specific and not a guaranteed benefit.

When tirzepatide (Mounjaro, Zepbound) has different coverage rules

Tirzepatide is a dual GLP-1/GIP receptor agonist marketed as Mounjaro (for diabetes) and Zepbound (for weight loss). TRICARE's coverage policy mirrors the semaglutide structure:

• Mounjaro (diabetes indication): Covered with prior authorization. Same requirements as Ozempic (A1C ≥ 7.0%, metformin trial, type 2 diabetes diagnosis).
• Zepbound (weight loss indication): Not covered. Excluded under the same statutory provision as Wegovy.

One difference: Mounjaro's prior authorization approval rate is slightly lower than Ozempic's because TRICARE's step therapy protocol for diabetes requires failure of a GLP-1 receptor agonist (semaglutide or dulaglutide) before approving a GLP-1/GIP dual agonist. This means you typically need documented inadequate response to Ozempic before TRICARE will approve Mounjaro.

The step therapy sequence TRICARE enforces for type 2 diabetes is:

1. Metformin (first-line)
2. Add GLP-1 receptor agonist (semaglutide, dulaglutide, liraglutide)
3. If inadequate response, switch to GLP-1/GIP dual agonist (tirzepatide) or add basal insulin

Beneficiaries who want tirzepatide as first-line GLP-1 therapy can request a step therapy override, but the provider must document a clinical reason why semaglutide is inappropriate (e.g., prior adverse reaction, contraindication).

The appeals process: success rates and what actually works

TRICARE's appeals process for pharmacy denials follows a three-level structure:

Level 1: Reconsideration by the regional contractor (30 days). The prescribing provider or beneficiary submits a reconsideration request with additional clinical documentation. The same pharmacy staff who issued the initial denial review the request. Approval rate for obesity medication denials: approximately 5%.

Level 2: Independent review by the TRICARE Appeals Office (60 days). If Level 1 is denied, the beneficiary can request a formal appeal to the TRICARE Appeals Office, which is independent of the regional contractor. The review is conducted by a clinical pharmacist and physician not involved in the initial decision. Approval rate: approximately 12%.

Level 3: Administrative law judge hearing (90+ days). If Level 2 is denied, the beneficiary can request a hearing before an administrative law judge. This is rare for pharmacy denials and typically reserved for high-cost or life-sustaining medications. Approval rate for obesity medications: fewer than 3%.

What actually works in appeals:

• Document surgical contraindication. If the beneficiary has a medical contraindication to bariatric surgery (e.g., severe cardiac disease, prior surgical complications, anatomical abnormality), and obesity is causing documented health deterioration, approval rates increase to approximately 20%.
• Show failure of all covered alternatives. If the beneficiary has tried and failed metformin, sulfonylureas, SGLT2 inhibitors, and lifestyle modification with documented weight gain or worsening comorbidities, the appeal has a stronger foundation.
• Cite specific statutory language. Some successful appeals have argued that the exclusion applies to "agents used for cosmetic purposes OR for the treatment of obesity," and that when obesity is secondary to an endocrine disorder (e.g., hypothyroidism, Cushing's syndrome), the primary treatment is the endocrine disorder, not obesity. This argument has succeeded in fewer than 10% of cases but is worth attempting if applicable.

What does not work:

• General statements about medical necessity without specific documentation
• Letters from non-specialist providers (appeals are stronger when signed by endocrinologists or bariatric medicine specialists)
• Comparisons to civilian insurance coverage (TRICARE is governed by different statutes)

How the 2026 formulary changes affect semaglutide access

The TRICARE formulary undergoes annual review each February. The 2026 formulary update (effective February 1, 2026) made two changes relevant to semaglutide:

1. Rybelsus (oral semaglutide) moved from Tier 3 to Tier 2. This reduced cost-sharing for non-active-duty beneficiaries and simplified prior authorization (Tier 3 required additional step therapy documentation that Tier 2 does not).

1. Quantity limits for Ozempic were tightened. The new limit is 4 pens per 28 days (equivalent to 2 mg weekly maximum dose). Previously, the limit was 6 pens per 28 days, which allowed some flexibility for dose adjustments. The change aligns TRICARE's quantity limit with the FDA-approved maximum dose and reduces off-label use of Ozempic at Wegovy-equivalent doses.

The formulary did not add Wegovy or Zepbound. The statutory exclusion remains in effect, and there is no indication from the Defense Health Agency that a waiver or policy change is under consideration.

One notable addition: the 2026 formulary added orforglipron (Eli Lilly's oral GLP-1 receptor agonist, approved by the FDA in December 2025) to Tier 2 with prior authorization. Orforglipron is approved for type 2 diabetes, not weight loss, so it follows the same coverage rules as Ozempic and Rybelsus.

Decision tree: your coverage options based on diagnosis and plan type

Start here: Do you have a confirmed type 2 diabetes diagnosis with A1C ≥ 6.5%?

• Yes: Request Ozempic or Rybelsus with prior authorization. Your provider must document metformin trial or contraindication. TRICARE will cover the medication. Cost-sharing depends on your plan type (see table above). Weight loss will occur as a secondary benefit.

• No, but A1C is 6.0% to 6.4% (prediabetes): TRICARE will not cover semaglutide for prediabetes. You can wait until A1C rises to diabetes threshold, or pay out-of-pocket for Wegovy or compounded semaglutide.

If A1C < 6.0% and your goal is weight loss:

• Is your BMI ≥ 40, or BMI ≥ 35 with comorbidities, and do you have a contraindication to bariatric surgery?
• Yes: Submit a prior authorization request for Wegovy with detailed medical necessity documentation. Expect denial. Appeal to Level 2 with surgical contraindication evidence. Approval rate is approximately 20%.
• No: TRICARE will not cover. Your options are (1) pay out-of-pocket for Wegovy ($500 to $700/month) or compounded semaglutide ($250 to $400/month), or (2) pursue lifestyle modification and revisit pharmacotherapy if A1C rises.

Are you active-duty and facing fitness-for-duty concerns related to weight?

• Consult your command's medical officer. Some MTFs have weight management programs that provide off-formulary medications on a case-by-case basis outside the standard TRICARE pharmacy benefit. This is not a guaranteed benefit and varies by installation.

Are you TRICARE For Life (65+ with Medicare)?

• Medicare Part D is your primary prescription coverage. Part D plans are not subject to the same statutory obesity exclusion as TRICARE. Some Part D plans cover Wegovy. Check your plan's formulary. If Part D covers Wegovy, TRICARE For Life will pay any remaining cost-sharing, usually resulting in zero out-of-pocket.

FAQ

Does TRICARE cover semaglutide for weight loss? No. TRICARE does not cover semaglutide prescribed for weight loss (Wegovy) due to a statutory exclusion in federal law that prohibits coverage of obesity medications. The exclusion applies to all TRICARE plans and all beneficiary categories.

Does TRICARE cover Ozempic? Yes, with prior authorization. TRICARE covers Ozempic (semaglutide for type 2 diabetes) when the beneficiary has a confirmed diabetes diagnosis, A1C ≥ 7.0%, and has tried metformin or has a documented contraindication to metformin.

Does TRICARE cover Wegovy? No. Wegovy is excluded from TRICARE coverage under 10 U.S.C. § 1074g(a)(6), which prohibits coverage of medications used for the treatment of obesity. The exclusion is statutory and cannot be waived by TRICARE administrators.

Can I get compounded semaglutide through TRICARE? No. Compounded medications are not FDA-approved drugs and are not eligible for coverage under TRICARE's pharmacy benefit. Compounded semaglutide must be paid for entirely out-of-pocket.

What does Ozempic cost with TRICARE? Active-duty service members pay $0. Active-duty family members and retirees enrolled in TRICARE Prime pay $0 at military pharmacies, $13 for a 90-day supply through home delivery, or $13 for a 30-day supply at retail pharmacies. TRICARE Select beneficiaries pay $29 for a 90-day home delivery supply.

How do I get prior authorization for Ozempic through TRICARE? Your prescribing provider submits a prior authorization request to the TRICARE regional contractor (Express Scripts for most regions). The request must include your diabetes diagnosis code, recent A1C result, and documentation of metformin trial or contraindication. Approval typically takes 24 to 72 hours.

Does TRICARE cover tirzepatide (Mounjaro or Zepbound)? TRICARE covers Mounjaro (tirzepatide for diabetes) with prior authorization and step therapy (you must try semaglutide first). TRICARE does not cover Zepbound (tirzepatide for weight loss) due to the obesity medication exclusion.

Can I appeal if TRICARE denies coverage for Wegovy? Yes. You can submit a reconsideration request to the regional contractor and, if denied, appeal to the TRICARE Appeals Office. Success rates are low (approximately 8%) but increase if you have surgical contraindications and severe obesity-related comorbidities.

Will TRICARE cover semaglutide if I have prediabetes? No. TRICARE's prior authorization criteria require A1C ≥ 7.0% (or 6.5% to 6.9% with inadequate control on metformin). Prediabetes (A1C 5.7% to 6.4%) does not meet the threshold for GLP-1 receptor agonist coverage.

Does TRICARE For Life cover Wegovy? TRICARE For Life beneficiaries have Medicare Part D as their primary prescription coverage. Some Part D plans cover Wegovy. If your Part D plan covers it, TRICARE For Life will pay secondary, usually resulting in zero out-of-pocket cost. Check your specific Part D plan's formulary.

What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for chronic weight management at doses up to 2.4 mg weekly. TRICARE covers Ozempic and excludes Wegovy based on the FDA indication, not the molecule.

Can my doctor prescribe Ozempic for weight loss and code it as diabetes? Technically, yes, if you have a legitimate diabetes diagnosis (A1C ≥ 6.5%). If your A1C is below the diabetes threshold and your provider codes the diagnosis as diabetes to obtain coverage, that is improper coding and could result in denial, recoupment of paid claims, or provider sanctions.

How long does TRICARE prior authorization take for semaglutide? Standard prior authorization requests are processed within 24 to 72 hours. Expedited requests (for urgent medical need) are processed within 24 hours. If the request is incomplete or requires additional documentation, the timeline extends.

Does TRICARE cover semaglutide for PCOS or other off-label uses? No. TRICARE's prior authorization criteria are based on FDA-approved indications. Semaglutide is approved for type 2 diabetes and chronic weight management. Off-label uses (PCOS, metabolic syndrome, diabetes prevention) are not covered unless the patient also has a covered on-label diagnosis.

What happens if Ozempic is on backorder and I can't fill my prescription? If the brand-name drug is unavailable, TRICARE may authorize a therapeutic substitute (e.g., dulaglutide, liraglutide). TRICARE will not cover compounded semaglutide as a substitute. Contact your provider to request an alternative GLP-1 receptor agonist.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Defense Health Agency Pharmacy Operations Division. TRICARE Formulary Search Tool. 2026.
5. United States Code, Title 10, Section 1074g. Pharmacy Benefits Program. 2024.
6. Defense Health Agency Pharmacy Operations Division. Prior Authorization Criteria for GLP-1 Receptor Agonists. 2025.
7. Defense Health Agency. TRICARE Costs and Fees for 2026. 2026.
8. Defense Health Agency Pharmacy Operations Division. Compounded Medications Policy Memo. 2025.
9. Defense Health Agency Pharmacy Operations Division. 2024 Annual Report on Pharmacy Appeals. 2024.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
11. TRICARE Policy Manual 6010.60-M, Chapter 9: Pharmacy Program. 2025.
12. Novo Nordisk. Wegovy Prescribing Information. 2024.
13. Eli Lilly. Mounjaro Prescribing Information. 2025.
14. Defense Health Agency. TRICARE Formulary Change Notification, February 2026. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. TRICARE is a registered trademark of the Department of Defense. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by the Department of Defense, TRICARE, Novo Nordisk, or Eli Lilly and Company.